Skip to main content
NTRA logo

NTRA · Natera, Inc. · Documents

Track NTRA — free
$294.75 -24.34 (-7.63%) Play latest call Q3 2026 earnings call transcript
Market Cap
$41.83B
Shares
145.00M
Volume · Nov 16 2.34M Avg daily vol (3M) 1.74M

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Revenue $2.31B up 35.9% 10-K filed Feb 27, 2026 Quarterly report FY2026 Q3 Revenue $793.98M up 34.1% 10-Q filed Nov 5, 2026 Latest results Natera Q3 revenue $794.0M, raises 2026 guidance by $140M 8-K filed Nov 5, 2026 Earnings call Q3 2026 earnings call Held Nov 5, 2026
2026
Nov 12
Registration statement S-3ASR
68,023 shares registered for potential resale

Natera registered 68,023 shares for potential resale by unnamed, non-affiliated selling stockholders. The total includes 45,533 closing shares issued on or about November 10, 2026 and an estimated 22,490 additional shares; Natera receives no proceeds.

Read from the first part of this long document
3 source passages
This prospectus relates to the potential resale from time to time of up to an aggregate of 68,023 shares (“Resale Shares”) of common stock, par value $0.0001 per share, of Natera, Inc. (the “Company”) by certain unnamed, non-affiliated selling stockholders described in this prospectus (the “Selling Stockholders”). The Resale Shares consist of (i) 45,533 shares (the “Closing Shares”) of the Company’s common stock issued to the Selling Stockholders on or about November 10, 2026, in connection with the closing of the transactions contemplated by that certain Agreement and Plan of Merger, dated as of November 2, 2026 (the “Merger Agreement”), by and among the Company, two wholly owned merger subsidiaries of the Company, a privately held company (the “Acquired Company”) and a stockholder representative, and (ii) an estimated 22,490 additional shares that may become issuable to the Selling Stockholders after the closing pursuant to the Merger Agreement (the “Potentially Issuable Shares”) We are not offering or selling any of the Resale Shares and we will not receive any proceeds from the sale of the Resale Shares by the Selling Stockholders pursuant to this prospectus. Open the document at this passage
Nov 10
Investor event
Revenue target reaches $6 billion by 2029

Natera targets $6 billion in revenue by 2029, using $14.50 Signatera ASP versus $12.90 today as an illustrative path. Solomon became CEO immediately, with operating and commercial structures unchanged.

5 source passages
what are the kind of some indicative assumptions one could use to get to $6 billion in revenue by 2029? $14.50 as an ASP for Signatera. Compare that to the current ASP of $12.90. So you have a new CEO, effective immediately. Tell me about Solomon. So our meeting cadences, the decisions that we make, our approach to how we size territories, how we measure performance, none of those things are going to change. We'll have colorectal cancer much quicker than that, but I'm very excited about that as the next chapter for Natera. Open the document at this passage
Nov 9
Investor event
Solomon Moshkevich targets $6 billion revenue in 2029

Natera CEO Solomon Moshkevich targets $6 billion in revenue for 2029; Signatera is expected to generate a little over a billion this year, with the fine study readout expected in the back half of next year.

6 source passages
Solomon Moshkevich, CEO Yeah, so Solomon is the 40th or 41st employee that joined Natera in 2011. The $6 billion 2029 revenue target. As Signatera has evolved from being something that you would use in a targeted setting for colorectal cancer and breast cancer, and evolved to more of a liquid CT scan. Signaterra is going to be something that, you know, there's, you know, a little over a billion in revenue this year. We're very excited about the fine study readout. I expect that next year. Probably back half, right? Open the document at this passage
Nov 5
Earnings call
Solomon succeeds Steve as CEO as revenue guidance rises

Natera says Solomon will succeed Steve as CEO, raising full-year 2026 revenue guidance to $3 billion $5 million-$3 billion $35 million and targeting $6 billion in 2029.

4 source passages
I am stepping down from the CEO role, as now is an excellent time to transition to new leadership for Natera. I'm very pleased to be handing the keys over to my friend and colleague, Solomon. Given the strength of the third quarter, we are raising our full year 2026 revenue guidance to a range of $3 billion $5 million to $3 billion $35 million, up from the $2.85 billion to $2.91 billion on our last call. We're setting the goal to double revenues in the next three years, reaching $6 billion in revenue in 2029. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Revenue rose 34.1% as net loss narrowed 31.6%

Natera reported that total revenues increased $201.8 million, or 34.1%, in the three months ended September 30, 2026, while net loss narrowed 31.6%. For the nine months, revenue was $2,243.4 million and net loss was $212.0 million.

Revenue $793.98M ▲ 34.1% Net loss $59.91M Diluted EPS -$0.42
Read from the MD&A section
4 source passages
Total revenues for the three months ended September 30, 2026 increased by $201.8 million, or 34.1%, when compared to the three months ended September 30, 2025. Net loss | (59,912) | (87,544) | 27,632 | (31.6%) For the nine months ended September 30, 2026, total revenues were $2,243.4 million compared to $1,640.6 million in the nine months ended September 30, 2025. Our net loss for the nine months ended September 30, 2026 and 2025 was $212.0 million and $255.4 million, respectively. Open the document at this passage
Nov 5
Current report 8-K
Natera Q3 revenue $794.0M, raises 2026 guidance by $140M

Natera reported third quarter 2026 total revenues of $794.0 million, up 34.1% from $592.2 million, with gross margin of 64.7% and a net loss of $59.9 million, or ($0.42) per diluted share. It raised 2026 revenue guidance to $3.005 billion - $3.035 billion and processed approximately 1,093,100 tests.

Financial results
5 source passages
Generated total revenues of $794.0 million in the third quarter of 2026, compared to $592.2 million in the third quarter of 2025, an increase of 34.1%. Raised 2026 annual revenue guidance by $140 million at the midpoint, from $2.850 billion - $2.910 billion to $3.005 billion - $3.035 billion. Natera’s net loss for the third quarter of 2026 was $59.9 million, or ($0.42) per diluted share Processed approximately 1,093,100 tests in the third quarter of 2026, compared to approximately 893,600 tests in the third quarter of 2025, an increase of 22.3%. Generated a gross margin1 of 64.7% in the third quarter of 2026, compared to a gross margin1 of 64.9% in the third quarter of 2025. Open the document at this passage
Aug 7
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $752.75M ▲ 37.7% Net loss $66.97M Diluted EPS -$0.47
May 8
Quarterly report 10-Q FY2026 Q1, ended Mar 31
Quarterly report for FY2026 Q1 AI summary on its way
Revenue $696.64M ▲ 38.8% Net loss $85.09M Diluted EPS -$0.60
Apr 23
Proxy statement DEF 14A Meeting Jun 11, 2026
Proxy statement AI summary on its way
Feb 27
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Revenue $2.31B ▲ 35.9% Net loss $208.16M Diluted EPS -$1.52
2025
Feb 28
Annual report 10-K FY2024, ended Dec 31
Annual report for FY2024
Revenue $1.7B ▲ 56.7% Net loss $190.43M Diluted EPS -$1.53
2024
Showing 1–50 of 152 documents
Key facts CIK 1604821 CUSIP 632307104 13F (30d) 737 filings 686 filers Visit website Investor relations